Adma Biologics | ADMA - Gross Profit On Sales

Stock Price
9.83
Daily Change
0.57 6.16%
Monthly
-37.82%
Yearly
-49.30%
Q2 Forecast
8.91

Adma Biologics reported $88.82M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 88.82M 13.19M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Takeda JPY 790.55B 262.97B Dec/2025